Renalytix - Profit Margin 2020-2024 | RNLXY
Current and historical gross margin, operating margin and net profit margin for Renalytix - (RNLXY) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Renalytix - net profit margin as of December 31, 2024 is 0%.
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.047B | $0.003B |
| Renalytix plc is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care. Renalytix plc, formerly known as RENALYTIX AI, is based in NEW YORK. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $48.330B | 58.97 |
| Tempus AI (TEM) | United States | $12.432B | 0.00 |
| Doximity (DOCS) | United States | $10.168B | 42.09 |
| Hims & Hers Health (HIMS) | United States | $9.274B | 75.98 |
| IRhythm Technologies (IRTC) | United States | $5.625B | 0.00 |
| Hinge Health (HNGE) | United States | $3.490B | 0.00 |
| Privia Health (PRVA) | United States | $2.876B | 180.23 |
| Heartflow (HTFL) | United States | $2.715B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $2.376B | 39.32 |
| 10x Genomics (TXG) | United States | $1.898B | 0.00 |
| Enovis (ENOV) | United States | $1.604B | 8.43 |
| Omnicell (OMCL) | United States | $1.601B | 32.73 |
| Clover Health Investments (CLOV) | United States | $1.368B | 0.00 |
| Azenta (AZTA) | United States | $1.346B | 58.74 |
| Phreesia (PHR) | United States | $1.319B | 0.00 |
| Schrodinger (SDGR) | United States | $1.309B | 0.00 |
| Claritev (CTEV) | United States | $1.141B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.807B | 0.00 |
| Evolent Health (EVH) | United States | $0.583B | 0.00 |
| Talkspace (TALK) | United States | $0.571B | 113.67 |
| Butterfly Network (BFLY) | United States | $0.561B | 0.00 |
| Veradigm (MDRX) | United States | $0.523B | 0.00 |
| Standard BioTools (LAB) | United States | $0.435B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.396B | 0.00 |
| Carlsmed (CARL) | United States | $0.363B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.295B | 0.00 |
| TruBridge (TBRG) | United States | $0.292B | 13.39 |
| CapsoVision (CV) | United States | $0.221B | 0.00 |
| Outset Medical (OM) | United States | $0.214B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.212B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.199B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.180B | 0.00 |
| Insight Molecular Diagnostics (IMDX) | United States | $0.179B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.167B | 0.00 |
| CareCloud (CCLD) | United States | $0.147B | 8.06 |
| EUDA Health Holdings (EUDA) | Singapore | $0.127B | 0.00 |
| Pulmonx (LUNG) | United States | $0.078B | 0.00 |
| NetraMark Holdings (AINMF) | Canada | $0.075B | 0.00 |
| American Well (AMWL) | United States | $0.068B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.057B | 0.00 |
| HeartBeam (BEAT) | United States | $0.057B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.040B | 0.00 |
| 111 (YI) | China | $0.036B | 0.00 |
| Precipio (PRPO) | United States | $0.032B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.026B | 0.00 |
| Lunai Bioworks (LNAI) | United States | $0.022B | 0.00 |
| Zhongchao (ZCMD) | China | $0.018B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.016B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.011B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.009B | 0.00 |
| PROFUSA (PFSA) | United States | $0.008B | 0.00 |
| HeartSciences (HSCS) | United States | $0.007B | 0.00 |
| Movano (MOVE) | United States | $0.004B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.002B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.002B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.001B | 0.00 |